Ikarian Capital’s Frazier Lifesciences Acquisition Corporation Unit FLACU Stock Holding History

Ikarian Capital’s Portfolio FLACU Stock Details FLACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-941	Closed	-$9K	–	218
2021 Q4	$9K	Sell	941 -72,177	-99%	-$723K	﹤0.01%	182
2021 Q3	$725K	Sell	73,118 -1,882	-3%	-$18.9K	0.05%	173
2021 Q2	$756K	Hold	75,000	–	–	0.06%	171
2021 Q1	$766K	Buy	+75,000	New	+$799K	0.03%	246

Other funds holding FLACU

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

CIM

Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Ikarian Capital's FLACU Position: Q1 2022 in Review

Ikarian Capital sold out of Frazier Lifesciences Acquisition Corporation Unit (FLACU) in Q1 2022, closing a stake of 941 shares — an estimated $9K sold.

Ikarian Capital first reported a position in FLACU in Q1 2021 and held it in 4 quarters. The position peaked at $766K in Q1 2021. 21 funds tracked by Wall St. Rank hold FLACU as of Q1 2022.

Ikarian Capital reported no remaining Frazier Lifesciences Acquisition Corporation Unit position as of Q1 2022 after selling out during the quarter.
Ikarian Capital sold 941 Frazier Lifesciences Acquisition Corporation Unit shares in Q1 2022, an estimated $9K.
Ikarian Capital first reported a position in Frazier Lifesciences Acquisition Corporation Unit in Q1 2021 and held it in 4 quarters.
Ikarian Capital's Frazier Lifesciences Acquisition Corporation Unit position peaked at $766K in Q1 2021.
21 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Unit as of Q1 2022.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.